Advanced Enzyme Technologies Ltd
Advanced Enzyme Technologies Limited is engaged in the business of manufacturing and sales of enzymes.[1]
- Market Cap ₹ 4,361 Cr.
- Current Price ₹ 390
- High / Low ₹ 571 / 334
- Stock P/E 29.7
- Book Value ₹ 120
- Dividend Yield 1.31 %
- ROCE 15.2 %
- ROE 11.2 %
- Face Value ₹ 2.00
Pros
- Company is almost debt free.
- Company has been maintaining a healthy dividend payout of 20.9%
Cons
- Stock is trading at 3.25 times its book value
- The company has delivered a poor sales growth of 8.26% over past five years.
- Company has a low return on equity of 10.6% over last 3 years.
- Promoter holding has decreased over last 3 years: -9.60%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Part of Nifty Total Market BSE Allcap BSE Healthcare BSE SmallCap Nifty Microcap 250
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
219 | 239 | 222 | 293 | 329 | 391 | 420 | 444 | 502 | 529 | 541 | 624 | 619 | |
130 | 189 | 131 | 155 | 177 | 226 | 236 | 241 | 269 | 327 | 382 | 418 | 417 | |
Operating Profit | 90 | 50 | 91 | 138 | 152 | 165 | 184 | 203 | 233 | 203 | 158 | 206 | 203 |
OPM % | 41% | 21% | 41% | 47% | 46% | 42% | 44% | 46% | 46% | 38% | 29% | 33% | 33% |
4 | 1 | 1 | -3 | 3 | 1 | 5 | 6 | 9 | 6 | 21 | 21 | 25 | |
Interest | 10 | 13 | 9 | 8 | 4 | 9 | 5 | 4 | 3 | 3 | 3 | 4 | 3 |
Depreciation | 8 | 10 | 9 | 9 | 13 | 18 | 21 | 26 | 29 | 35 | 35 | 35 | 35 |
Profit before tax | 76 | 28 | 74 | 118 | 137 | 139 | 162 | 179 | 210 | 171 | 140 | 188 | 189 |
Tax % | 34% | 23% | 31% | 35% | 32% | 33% | 28% | 26% | 28% | 28% | 26% | 27% | |
50 | 21 | 51 | 77 | 93 | 94 | 116 | 133 | 151 | 124 | 104 | 137 | 141 | |
EPS in Rs | 4.52 | 1.85 | 4.60 | 6.97 | 8.20 | 8.07 | 9.95 | 11.58 | 13.06 | 10.70 | 9.45 | 11.92 | 12.26 |
Dividend Payout % | 7% | 6% | 4% | 3% | 5% | 6% | 6% | 5% | 7% | 9% | 11% | 43% |
Compounded Sales Growth | |
---|---|
10 Years: | 10% |
5 Years: | 8% |
3 Years: | 8% |
TTM: | 6% |
Compounded Profit Growth | |
---|---|
10 Years: | 22% |
5 Years: | 5% |
3 Years: | 0% |
TTM: | 16% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | 20% |
3 Years: | 4% |
1 Year: | 7% |
Return on Equity | |
---|---|
10 Years: | 15% |
5 Years: | 13% |
3 Years: | 11% |
Last Year: | 11% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 |
Reserves | 140 | 145 | 188 | 256 | 442 | 537 | 657 | 817 | 949 | 1,066 | 1,213 | 1,302 | 1,319 |
186 | 167 | 115 | 101 | 54 | 67 | 35 | 28 | 28 | 35 | 34 | 47 | 47 | |
48 | 73 | 92 | 71 | 65 | 102 | 91 | 104 | 150 | 137 | 142 | 150 | 161 | |
Total Liabilities | 396 | 406 | 417 | 450 | 583 | 727 | 805 | 971 | 1,149 | 1,260 | 1,411 | 1,521 | 1,549 |
287 | 287 | 287 | 285 | 421 | 491 | 495 | 563 | 604 | 619 | 649 | 650 | 665 | |
CWIP | 2 | 2 | 5 | 7 | 8 | 11 | 10 | 10 | 10 | 15 | 22 | 41 | 34 |
Investments | 0 | 0 | 0 | 0 | 0 | 0 | 111 | 124 | 121 | 102 | 360 | 403 | 396 |
107 | 117 | 125 | 158 | 153 | 226 | 188 | 275 | 414 | 524 | 380 | 427 | 454 | |
Total Assets | 396 | 406 | 417 | 450 | 583 | 727 | 805 | 971 | 1,149 | 1,260 | 1,411 | 1,521 | 1,549 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
41 | 43 | 54 | 93 | 107 | 116 | 129 | 141 | 163 | 122 | 140 | 141 | |
-40 | -25 | -15 | -10 | -60 | -60 | -124 | -43 | -27 | 2 | -286 | -65 | |
-3 | -20 | -36 | -63 | -65 | -2 | -43 | -39 | -26 | -48 | -26 | -59 | |
Net Cash Flow | -2 | -1 | 2 | 21 | -18 | 54 | -38 | 60 | 109 | 75 | -171 | 17 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 65 | 49 | 61 | 52 | 55 | 55 | 51 | 61 | 63 | 61 | 68 | 58 |
Inventory Days | 318 | 387 | 403 | 358 | 352 | 339 | 363 | 361 | 346 | 402 | 343 | 375 |
Days Payable | 121 | 81 | 89 | 68 | 57 | 78 | 46 | 43 | 56 | 60 | 67 | 40 |
Cash Conversion Cycle | 262 | 356 | 374 | 342 | 351 | 315 | 369 | 379 | 353 | 404 | 344 | 393 |
Working Capital Days | 95 | 5 | -4 | 40 | 106 | 82 | 90 | 100 | 104 | 122 | 117 | 106 |
ROCE % | 26% | 12% | 25% | 36% | 31% | 25% | 24% | 22% | 22% | 15% | 12% | 15% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Acquisition
5 Dec - Approval for formation of Starya Labs, a new subsidiary.
-
Intimation - Regulation 30 Of The SEBI (LODR) Regulations, 2015
5 Dec - Approval for formation of Starya Labs, Inc. in California.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
29 Nov - Intimation of Analyst/Investor Meeting scheduled.
-
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
19 Nov - Transcript of Q2 FY '25 earnings conference call.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
13 Nov - Audio recording of conference call on Q2 results.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2006
from bse
Concalls
-
Nov 2024Transcript PPT REC
-
Aug 2024Transcript PPT
-
May 2024Transcript PPT
-
Feb 2024Transcript PPT REC
-
Nov 2023Transcript PPT
-
Aug 2023Transcript PPT
-
May 2023Transcript PPT
-
Feb 2023Transcript PPT
-
Nov 2022Transcript PPT
-
Aug 2022Transcript PPT
-
May 2022Transcript PPT
-
Feb 2022Transcript PPT
-
Nov 2021Transcript PPT
-
Nov 2021TranscriptNotesPPT
-
Oct 2021TranscriptNotesPPT
-
Sep 2021Transcript PPT
-
Aug 2021TranscriptNotesPPT
-
Jun 2021Transcript PPT
-
Mar 2021TranscriptPPT
-
Feb 2021Transcript PPT
-
Dec 2020TranscriptNotesPPT
-
Nov 2020Transcript PPT
-
Aug 2020Transcript PPT
-
Aug 2020TranscriptNotesPPT
-
Jun 2020Transcript PPT
-
Mar 2020TranscriptPPT
-
Feb 2020Transcript PPT
-
Feb 2020TranscriptNotesPPT
-
Nov 2019Transcript PPT
-
Nov 2019TranscriptNotesPPT
-
Nov 2019TranscriptNotesPPT
-
Aug 2019Transcript PPT
-
May 2019Transcript PPT
-
Nov 2018Transcript PPT
-
Aug 2018Transcript PPT
-
Jun 2018Transcript PPT
-
May 2018TranscriptNotesPPT
-
May 2018TranscriptNotesPPT
-
May 2018TranscriptNotesPPT
-
Feb 2018Transcript PPT
-
Nov 2017TranscriptPPT
-
Sep 2017Transcript PPT
-
Jun 2017TranscriptNotesPPT
-
Jun 2017Transcript PPT
-
May 2017TranscriptNotesPPT
-
Mar 2017TranscriptNotesPPT
-
Feb 2017Transcript PPT
-
Nov 2016Transcript PPT
-
Nov 2016TranscriptPPT
Market Position
The Co. is the 1st Indian enzyme company with 2nd highest market share in India. It is the 2nd listed integrated enzyme player globally. [1]